R&D Center

GJMEDI INC.

Main pipeline



2022
2023
2025
2027

Indication
Discovery
Preclinical
Phase1
Phase2
Phase3
Pancreatic cancer inhibitor 1 (CY101)


Pancreatic cancer inhibitor 2 (GJ101)


Lung cancer inhibitor (GJ501)


Colorectal cancer inhibitor (GJ105)


Cancer of the liver inhibitor (GJ108)


A cure for dementia (GJ106)


Anti-inflammatory drugs (GJ107)


Virus inhibitors


Diagnosis kits




CUSTOMER CENTER

+82-51-581-2544
Mon - Fri AM 09:00 - 18:00
Lunch pm 12:00 - pm 01:00
Sat.Sun.Red-Day Off


DELIVERY

Head office : 407B, Hyowon University-Industry Cooperation Bldg., 2 Busandaehak-ro 63beon-gil, Geumjeong-gu, Busan, 46241, Republic of KOREA
EMAIL : infogjmedi@naver.com

ACCOUNT

NH BANK 301-0263-4494-61 (Head office)
 Account Holder : GJMEDI INC. 


Business name : GJMEDI INC.  CEO : Mi Suk Jeong
Business registration number : 173-88-01396
Online sales registration : No. 2020-Busan Geumjeong-0259
Personal information manager: Mi Suk Jeong
Tel: +82-51-581-2544 / Fax: +82-51-581-2545 /infogjmedi@naver.com